Michael T Cronin1, Jane L Di Gennaro1,2, R Scott Watson1,3, Leslie A Dervan4,5. 1. Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Washington, M/S FA2.112, 4800 Sand Point Way NE, Seattle, WA, USA. 2. Center for Clinical and Translational Research, Seattle Children's Research Institute, 2001 Eighth Ave, Suite 400, Seattle, WA, USA. 3. Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, 2001 Eighth Ave, Suite 400, Seattle, WA, USA. 4. Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Washington, M/S FA2.112, 4800 Sand Point Way NE, Seattle, WA, USA. leslie.dervan@seattlechildrens.org. 5. Center for Clinical and Translational Research, Seattle Children's Research Institute, 2001 Eighth Ave, Suite 400, Seattle, WA, USA. leslie.dervan@seattlechildrens.org.
Abstract
PURPOSE: The aim of this study was to evaluate outcomes of pediatric intensive care unit (PICU) patients with delirium treated with haloperidol or quetiapine compared with propensity-matched, untreated patients. MATERIALS AND METHODS: A single-center retrospective cohort study was conducted including PICU admissions of ≥ 48 h for children ≥ 2 months old with a positive delirium screening score (Cornell Assessment of Pediatric Delirium ≥ 9). We generated propensity scores for the likelihood of receiving treatment with haloperidol or quetiapine using logistic regression, and matched untreated to treated patients 2:1 to compare outcomes between groups. RESULTS: Among 846 eligible admissions, 27 were treated with haloperidol or quetiapine (3.2%). Time to first delirium-free score was similar for treated versus untreated patients. Treated patients had no significant change in delirium scores following treatment, while untreated patients' scores improved after the comparable matching time. Compared with untreated patients, haloperidol-treated patients had more subsequent days of delirium and exposure to neuromuscular blockade. Quetiapine-treated patients had more subsequent days of mechanical ventilation and exposure to neuromuscular blockade, longer PICU length of stay, and higher likelihood of functional decline at ICU discharge. CONCLUSIONS: In our small, single-center study, patients treated with haloperidol or quetiapine showed no short-term improvement in delirium screening scores after starting treatment when compared with untreated, propensity score-matched patients. In addition, clinical outcomes were not improved or were worse among treated patients. A prospective trial is needed to evaluate whether antipsychotic medications benefit PICU patients with delirium.
PURPOSE: The aim of this study was to evaluate outcomes of pediatric intensive care unit (PICU) patients with delirium treated with haloperidol or quetiapine compared with propensity-matched, untreated patients. MATERIALS AND METHODS: A single-center retrospective cohort study was conducted including PICU admissions of ≥ 48 h for children ≥ 2 months old with a positive delirium screening score (Cornell Assessment of Pediatric Delirium ≥ 9). We generated propensity scores for the likelihood of receiving treatment with haloperidol or quetiapine using logistic regression, and matched untreated to treated patients 2:1 to compare outcomes between groups. RESULTS: Among 846 eligible admissions, 27 were treated with haloperidol or quetiapine (3.2%). Time to first delirium-free score was similar for treated versus untreated patients. Treated patients had no significant change in delirium scores following treatment, while untreated patients' scores improved after the comparable matching time. Compared with untreated patients, haloperidol-treated patients had more subsequent days of delirium and exposure to neuromuscular blockade. Quetiapine-treated patients had more subsequent days of mechanical ventilation and exposure to neuromuscular blockade, longer PICU length of stay, and higher likelihood of functional decline at ICU discharge. CONCLUSIONS: In our small, single-center study, patients treated with haloperidol or quetiapine showed no short-term improvement in delirium screening scores after starting treatment when compared with untreated, propensity score-matched patients. In addition, clinical outcomes were not improved or were worse among treated patients. A prospective trial is needed to evaluate whether antipsychotic medications benefit PICU patients with delirium.
Authors: Heidi A B Smith; D Catherine Fuchs; Pratik P Pandharipande; Frederick E Barr; E Wesley Ely Journal: Crit Care Clin Date: 2009-07 Impact factor: 3.598
Authors: Chani Traube; Gabrielle Silver; Ron W Reeder; Hannah Doyle; Emily Hegel; Heather A Wolfe; Christopher Schneller; Melissa G Chung; Leslie A Dervan; Jane L DiGennaro; Sandra D W Buttram; Sapna R Kudchadkar; Kate Madden; Mary E Hartman; Mary L deAlmeida; Karen Walson; Erwin Ista; Manuel A Baarslag; Rosanne Salonia; John Beca; Debbie Long; Yu Kawai; Ira M Cheifetz; Javier Gelvez; Edward J Truemper; Rebecca L Smith; Megan E Peters; A M Iqbal O'Meara; Sarah Murphy; Abdulmohsen Bokhary; Bruce M Greenwald; Michael J Bell Journal: Crit Care Med Date: 2017-04 Impact factor: 7.598
Authors: Omayma A Kishk; Shari Simone; Allison B Lardieri; Ana Lia Graciano; Jamie Tumulty; Sarah Edwards Journal: J Pediatr Pharmacol Ther Date: 2019 May-Jun
Authors: Timothy D Girard; Matthew C Exline; Shannon S Carson; Catherine L Hough; Peter Rock; Michelle N Gong; Ivor S Douglas; Atul Malhotra; Robert L Owens; Daniel J Feinstein; Babar Khan; Margaret A Pisani; Robert C Hyzy; Gregory A Schmidt; William D Schweickert; R Duncan Hite; David L Bowton; Andrew L Masica; Jennifer L Thompson; Rameela Chandrasekhar; Brenda T Pun; Cayce Strength; Leanne M Boehm; James C Jackson; Pratik P Pandharipande; Nathan E Brummel; Christopher G Hughes; Mayur B Patel; Joanna L Stollings; Gordon R Bernard; Robert S Dittus; E Wesley Ely Journal: N Engl J Med Date: 2018-10-22 Impact factor: 91.245
Authors: Juliana Barr; Gilles L Fraser; Kathleen Puntillo; E Wesley Ely; Céline Gélinas; Joseph F Dasta; Judy E Davidson; John W Devlin; John P Kress; Aaron M Joffe; Douglas B Coursin; Daniel L Herr; Avery Tung; Bryce R H Robinson; Dorrie K Fontaine; Michael A Ramsay; Richard R Riker; Curtis N Sessler; Brenda Pun; Yoanna Skrobik; Roman Jaeschke Journal: Am J Health Syst Pharm Date: 2013-01-01 Impact factor: 2.637
Authors: Chani Traube; Elizabeth A Mauer; Linda M Gerber; Savneet Kaur; Christine Joyce; Abigail Kerson; Charlene Carlo; Daniel Notterman; Stefan Worgall; Gabrielle Silver; Bruce M Greenwald Journal: Crit Care Med Date: 2016-12 Impact factor: 7.598